Rapid Micro Biosystems Past Earnings Performance
Past criteria checks 0/6
Rapid Micro Biosystems's earnings have been declining at an average annual rate of -0.8%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 6.3% per year.
Key information
-0.8%
Earnings growth rate
92.1%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 6.3% |
| Return on equity | -57.4% |
| Net Margin | -184.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) Shares Leap 25% Yet They're Still Not Telling The Full Story
Nov 02
Is Rapid Micro Biosystems (NASDAQ:RPID) In A Good Position To Invest In Growth?
Oct 29A Piece Of The Puzzle Missing From Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 32% Share Price Climb
Aug 03We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate
Jun 30Rapid Micro to introduce RMBNucleus software for mold detection in pharma manufacturing
Oct 10Companies Like Rapid Micro Biosystems (NASDAQ:RPID) Are In A Position To Invest In Growth
May 09Earnings Release: Here's Why Analysts Cut Their Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Price Target To US$17.67
Mar 08We're Not Very Worried About Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate
Feb 07Revenue & Expenses Breakdown
How Rapid Micro Biosystems makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 26 | -48 | 36 | 15 |
| 30 Jun 24 | 25 | -50 | 37 | 14 |
| 31 Mar 24 | 23 | -52 | 37 | 14 |
| 31 Dec 23 | 23 | -52 | 38 | 13 |
| 30 Sep 23 | 21 | -58 | 41 | 13 |
| 30 Jun 23 | 19 | -61 | 42 | 13 |
| 31 Mar 23 | 18 | -60 | 42 | 12 |
| 31 Dec 22 | 17 | -61 | 42 | 13 |
| 30 Sep 22 | 18 | -59 | 40 | 12 |
| 30 Jun 22 | 20 | -68 | 37 | 12 |
| 31 Mar 22 | 22 | -69 | 34 | 11 |
| 31 Dec 21 | 23 | -78 | 30 | 10 |
| 30 Sep 21 | 23 | -77 | 26 | 9 |
| 30 Jun 21 | 22 | -63 | 21 | 8 |
| 31 Mar 21 | 18 | -60 | 18 | 7 |
| 31 Dec 20 | 16 | -45 | 16 | 7 |
| 31 Dec 19 | 17 | -27 | 13 | 5 |
Quality Earnings: RPID is currently unprofitable.
Growing Profit Margin: RPID is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RPID is unprofitable, and losses have increased over the past 5 years at a rate of 0.8% per year.
Accelerating Growth: Unable to compare RPID's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RPID is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-10.7%).
Return on Equity
High ROE: RPID has a negative Return on Equity (-57.36%), as it is currently unprofitable.